Drugs in MeSH Category Contrast Media

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	IOPAMIDOL	iopamidol	INJECTABLE;INJECTION	074629-004	Mar 31, 1998		DISCN	No	No
Bracco	RENO-60	diatrizoate meglumine	INJECTABLE;INJECTION	010040-016	Approved Prior to Jan 1, 1982		DISCN	No	No
Bracco	VARIBAR THIN HONEY	barium sulfate	SUSPENSION;ORAL	208143-006	Jan 23, 2018		RX	Yes	Yes
Cook Imaging	IOPAMIDOL-250	iopamidol	INJECTABLE;INJECTION	074881-002	Jul 28, 2000		DISCN	No	No
Fresenius Kabi Usa	IOPAMIDOL-250	iopamidol	INJECTABLE;INJECTION	074679-001	Apr 2, 1997		DISCN	No	No
Hospira	IOPAMIDOL-250 IN PLASTIC CONTAINER	iopamidol	INJECTABLE;INJECTION	074636-002	Dec 30, 1997		DISCN	No	No

Contrast Media Market Analysis and Financial Projection

The contrast media market is experiencing steady growth driven by technological advancements and increasing diagnostic needs, while its patent landscape reflects strategic maneuvers to sustain market exclusivity and address safety concerns. Here's a breakdown of key dynamics:

---

Market Dynamics

Growth Projections and Drivers

• The global contrast media market is projected to grow at a 4.1%–7.5% CAGR, expanding from $6.06 billion in 2024 to $9.7 billion by 2032[2][6][11][12].
• Primary drivers include:
  • Rising demand for diagnostic imaging (CT scans, MRIs, ultrasound) due to chronic diseases like cancer, cardiovascular disorders, and neurological conditions[6][12].
  • Aging populations and increased healthcare spending, particularly in North America (44% market share) and Asia-Pacific (fastest-growing region)[11][12].
  • Innovations such as nanosized agents and AI-powered tools (e.g., Subtle Medical’s software reducing gadolinium doses by 90%[13]).

Segment Insights

1. By Modality:

   • X-ray/CT contrast media (iodinated agents) dominate with ~70% market share[11].
   • MRI contrast media (gadolinium-based) are growing rapidly (3.8% CAGR) due to superior soft-tissue imaging[7][12].

2. By Application:

   • Neurological disorders lead (29.45% share), driven by gadolinium agents for brain imaging[11].
   • Cardiovascular applications are rising due to contrast-enhanced ultrasound and CT angiography[11].

Challenges

• Safety concerns: Nephrotoxicity from iodinated agents and gadolinium retention in tissues[8][16].
• Cost barriers: High expenses for advanced contrast agents and imaging equipment in developing regions[14].

---

Patent Landscape

Strategic Patenting Trends

• Post-approval patent filings: Over 70% of patents for top-selling drugs are filed after FDA approval, creating "patent thickets" to delay generics[4].
• Formulation patents: Example: EP0521880B2 covers non-ionic agents with sodium/calcium salts to improve safety[1].

Key Innovations and Licensing

• AI integration: Patents like Subtle Medical’s U.S. Patent No. 10,997,716 focus on reducing contrast dosage via deep learning[13].
• Licensing models: The Medicines Patent Pool (MPP) facilitates generic licensing in developing countries, boosting access but shifting R&D toward follow-on trials[5].

Regulatory Shifts

• FDA oversight: A 2022 law mandates regulating all contrast agents as drugs, increasing scrutiny on safety and efficacy data[17].

---

Competitive Landscape

• Major players: Bayer AG, GE Healthcare, Bracco, and Guerbet lead through acquisitions (e.g., GE’s purchase of BK Medical[11]) and product approvals (e.g., Bayer’s Gadavist for cardiac MRI[11]).
• Generics threat: Patent expirations (e.g., Magnevist[16]) are enabling cheaper alternatives, intensifying competition[6][15].

---

Future Outlook

• Emerging technologies: Nanoparticles and molecular imaging agents aim for targeted diagnostics with fewer side effects[16].
• Regional expansion: Asia-Pacific’s market will surge due to aging populations and increasing imaging center investments[6][12].

“AI software enables significantly reduced contrast agent dosage, improving patient safety while maintaining diagnostic accuracy.” — Subtle Medical CEO Enhao Gong on U.S. Patent No. 10,997,716[13]

---

In summary, the contrast media market is evolving through innovation in safety and AI, while patent strategies and regulatory changes reshape competition and accessibility. Balancing growth with patient safety remains critical as demand for advanced diagnostics grows.

References

1. https://patents.google.com/patent/EP0521880B2/en
2. https://www.factmr.com/report/contrast-media-market
3. https://en.wikipedia.org/wiki/VX_(nerve_agent)
4. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2818277
5. https://www.canadiancentreforhealtheconomics.ca/wp-content/uploads/2022/11/Wang-2022.pdf
6. https://www.marketsandmarkets.com/Market-Reports/contrast-media-market-911.html
7. https://www.marketresearchfuture.com/reports/contrast-media-market/market-analysis
8. https://pubmed.ncbi.nlm.nih.gov/21136062/
9. https://wipo-analytics.github.io/handbook/citations.html
10. https://pmc.ncbi.nlm.nih.gov/articles/PMC5452884/
11. https://market.us/report/contrast-media-market/
12. https://www.mordorintelligence.com/industry-reports/global-contrast-media-market-industry
13. https://subtlemedical.com/subtle-medical-awarded-breakthrough-patent-for-reduced-contrast-agent-dosage-in-medical-imaging-exams/
14. https://www.industryarc.com/Report/16791/contrast-mediacontrast-agent-market.html
15. https://www.zionmarketresearch.com/report/contrast-media-contrast-agent-market
16. https://pubmed.ncbi.nlm.nih.gov/24414380/
17. https://www.fdli.org/2023/03/regulating-contrast-agents-as-drugs-whats-next-for-fda/